Forbes Learns a Lesson, but Not the Right One: Censorship and Bias re: A Film Producer, A Cancer Doctor, And Their Critics

onforb.es/11pwse9
4/19/2013 @ 9:43PM
http://t.co/vh3cgAR6hW
“Speech is best countered by more speech”
http://www.forbes.com/sites/peterlipson/2013/04/19/a-film-producer-a-cancer-doctor-and-their-critics
Peter Lipson, Contributor

posted an article of a very dubious nature on Forbes (#Forbes), which censored (deleted) comments submitted and screen-captured as having been posted to the article comments section

What did Forbes do to rectify this embarrassing blunder?

Well, they did NOT do what Wikipedia is supposed to do (Do the RIGHT THING), they instead changed their comment acceptance function so that it now does NOT post the comments to the comment section; where they can be screen- saved to show that you submitted them, but now prevents the comments from being posted to the comments section before being reviewed by their censor(s)

I was able to submit comments and screen save them to show I submitted them, but the below, for example, was still censored

Thursday, 5/2/2013-ATTEMPT 1:

Didymus Thomas 30 minutes ago

Mr. Ogon, is this one of the Kurume, Japan case studies you were referring to?
Randomized Phase II Study of Hepatic Arterial Infusion with or without Antineoplastons as Adjuvant Therapy after Hepatectomy for liver Metastases from Colorectal Cancer. Annals of Oncology 2010;21:viii221

Reply

Didymus Thomas 20 minutes ago

Share your comment:
facebook
linkedin
twitter

Didymus Thomas 4 hours ago

Mr. Ogon, you commented:
“One further has to take into account the fact that Scamley has been known to employ idiosyncratic definitions, such as classifying tumor *growth* as “STABLE DISEASE” for “less than 50% reduction in size but no more than 50% increase in size of the tumor mass, lasting for at least twelve weeks.””
FDA has advised:
5/2007 – “Guidance for Industry – Food and Drug Administration”
“Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics”
“”STABLE DISEASE should not be a component of ORR”
“STABLE DISEASE can reflect the natural history of disease””
(Pg. 10 of 22 = actual pg. 7 of PDF)
“…STABLE DISEASE can be more accurately assessed by TTP or PFS analysis (see below)”
“Also, STABLE DISEASE can be more accurately assessed by TTP or PFS analysis (see below)”
(Pg. 11 of 22 = actual pg. 8 of PDF)
“Time to Progression and Progression-Free Survival”
“TTP – Time to Progression”
“PFS – Progression-Free Survival”
“TTP and PFS have served as primary endpoints for drug approval”
(Pg. 11 of 22 = actual pg. 8 of PDF)
And in addition, the below 2005 non-Burzynski study also uses “STABLE DISEASE?”
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children
Results of a multiinstitutional study (SJHG-98)

Reply

Didymus Thomas 15 minutes ago

Mr. Chapman, you commented:
” … the failure to publish any usable results from any single trial is grossly unethical”
“ The FDA’s Drug Review Process: Ensuring Drugs Are Safe and Effective” advises:
“[T]he emphasis in Phase 2 is on EFFECTIVENESS”
“This phase aims to obtain PRELIMINARY DATA on whether the drug works in people who have a certain disease or condition”
“Phase 3 studies begin if EVIDENCE of EFFECTIVENESS is shown in Phase 2″
“These studies gather more information about safety and EFFECTIVENESS, studying different populations and different dosages and using the drug in combination with other drugs”

Reply

Didymus Thomas 9 minutes ago

Securities and Exchange Commission (SEC) Form 10-Q for the quarterly period ended 5/31/2010 states:
1/13/2009 Company announced Company had reached an agreement with FDA for Company to move forward with pivotal Phase III clinical trial of combination Antineoplaston therapy plus radiation therapy in patients with newly diagnosed, diffuse, intrinsic brainstem gliomas (DBSG)
Agreement was made under FDA’s Special Protocol Assessment procedure, meaning design and planned analysis of Phase III study is acceptable to support regulatory submission seeking new drug approval
2/1/2010 Company entered into agreement with Cycle Solutions, Inc., dba ResearchPoint to initiate and manage pivotal Phase III clinical trial of combination Antineoplastons A10 and AS2-1 plus radiation therapy (RT) in patients with newly-diagnosed, diffuse, intrinsic brainstem glioma
ResearchPoint is currently conducting feasibility assessment
ResearchPoint has secured interest and commitment from number of sites selected
Upon completion of assessment, randomized, international phase III study will commence
Study’s objective is to compare overall survival of children with newly-diagnosed DBSG who receive combination Antineoplastons A10 and AS2-1 plus RT versus RT alone

Reply

Didymus Thomas 1 minute ago

2003-2006 phase II clinical trial preliminary reports.
The co-authors might include an oncologist:
Drugs R D.
2003;4(2):91-101
2004;5(6):315-26
Integr Cancer Ther.
2005 Jun;4(2):168-77
2006 Mar;5(1):40-7

Friday, 5/3/2013-ATTEMPT 2

(Note how I shortened the comment):

Thank you for submitting your comment:

New comments typically appear within 30 seconds.

Mr. Ogon, 5/2007 – “Guidance for Industry – Food and Drug Administration”
“Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics”
“Stable disease can reflect the natural history of disease”
“Also, stable disease can be more accurately assessed by TTP or PFS analysis”
“TTP – Time to Progression”
“PFS – Progression-Free Survival”
“TTP and PFS have served as primary endpoints for drug approval”
The below study also uses “stable disease”
Cancer. 2005 Jan 1;103(1):133-9 DOI: 10.1002/cncr.20741

Share your comment:

Saturday, 5/4/2013-ATTEMPT 3

Note how I further shortened the comment):

Thank you for submitting your comment:

New comments typically appear within 30 seconds.

Mr. Ogon, 5/2007 – “Guidance for Industry – Food and Drug Administration, Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics:” “Stable disease can reflect the natural history of disease”
This study uses “stable disease:”. Cancer. 2005 Jan 1;103(1):133-9 DOI: 10.1002/cncr.20741

Share your comment:
facebook
linkedin
twitter

Forbes posted the 1 below comment out of the above:

Didymus Thomas 3 days ago
Mr. Ogon, is this one of the Kurume, Japan case studies you were referring to?
Randomized Phase II Study of Hepatic Arterial Infusion with or without Antineoplastons as Adjuvant Therapy after Hepatectomy for liver Metastases from Colorectal Cancer. Annals of Oncology 2010;21:viii221

One would hope that Forbes would learn a lesson about censoring individual’s comments, but instead, it seems that they learned a lesson about how to block comments

Here is the BIAS exhibited by Forbes, as far as whose comments they did NOT “censor”

– = “The Skeptic” Critics
+ = Questioning “The Skeptic” Critics

– = 70
+ = 44

+ = 25 more

(pg. 1)

rjblaskiewicz –
guychapman –
Peter Lipson –
rjblaskiewicz –
Vered Yasur –
Angel of Life +
rjblaskiewicz –
guychapman –
guychapman –
Krista Cashatt +

(pg. 2)

Boris Ogon –
junkeeroo +
Boris Ogon –
Sarah
junkeeroo +
junkeeroo +
Boris Ogon –
rjblaskiewicz –
Kendra Sue Too +
Boris Ogon –

(pg. 3)

junkeeroo +
Boris Ogon –
junkeeroo +
guychapman –
FW –
Angel of Life +
rjblaskiewicz –
randy hinton +
Boris Ogon –
rjblaskiewicz –

(pg. 4)

lilady –
Vered Yasur –
junkeeroo +
Tina Patterson +
chriswinter +
guychapman –
Angel of Life +
Boris Ogon –
JGC2013 –
guychapman –

(pg. 5)

lilady –
Angel of Life +
Boris Ogon –
FW –
junkeeroo +
Angel of Life +
Peter Lipson –
Angel of Life +
junkeeroo +
Boris Ogon –

(pg. 6)

Paul Morgan –
guychapman –
JGC2013 –
junkeeroo +
FW –
junkeeroo +
rjblaskiewicz –
FW –
Angel of Life +
Angel of Life +

(pg. 7)

Angel of Life +
FW –
AstroturfWatch +
FW –
junkeeroo +
junkeeroo +
Angel of Life +
Peter Lipson –
AstroturfWatch +
AstroturfWatch +

(pg. 8)

FW –
AstroturfWatch +
Angel of Life +
FW –
FW –
AstroturfWatch +
FW –
rjblaskiewicz –
Boris Ogon –
Boris Ogon –

(pg. 9)

Lynne –
guychapman –
guychapman –
guychapman –
guychapman –
randy hinton +
guychapman –
Boris Ogon –
Boris Ogon –
guychapman –

(pg. 10)

guychapman –
randy hinton +
guychapman –
Sharon Hill –
oval wooki –
randy hinton +
guychapman –
JGC2013 –
guychapman –
AstroturfWatch +

(pg. 11)

guychapman –
Allen Jones –
claire G –
claire G –
randy hinton +
lilady –
Didymus Thomas +
lilady –
Didymus Thomas +
lilady –

(pg. 12)

Didymus Thomas +
lilady –
Didymus Thomas +
Didymus Thomas +
Didymus Thomas +
Didymus Thomas +

“The Skeptic” Critics
TOTAL
18-guychapman –
13-Boris Ogon –
10-FW –
_8-rjblaskiewicz –
_6-lilady –
_3-Peter Lipson –
_3-JGC2013 –
_2-claire G –
_2-Vered Yasur –
_1-Paul Morgan –
_1-Lynne –
_1-Sharon Hill –
_1-oval wooki –
_1-Allen Jones –
70-TOTAL

Questioning “The Skeptic” Critics
TOTAL
12-junkeeroo +
10-Angel of Life +
_7-Didymus Thomas +
_6-AstroturfWatch +
_5-randy hinton +
_1-Krista Cashatt +
_1-Kendra Sue Too +
_1-Tina Patterson +
_1-chriswinter +
44-TOTAL

_1-Sarah (neutral)

“The Skeptic” Critics

guychapman (Guy Chapman, @SceptiGuy, @vGuyUK)
http://www.chapmancentral.co.uk/blahg/
A United Kingdom (UK) blahg

Guy Chapman comments on “Orac’s”:
(http://www.scienceblogs.com/Insolence)

FW (@frozenwarning): I work for the NHS in the UK

frozenwarning comments on “Orac’s”:
(http://www.scienceblogs.com/Insolence)

rjblaskiewicz (Bob Blaskiewicz, R.J. Blaskiewicz, @rjblaskiewicz)
http://www.skepticalhumanities.com

Bob Blaskiewicz comments on “Orac’s”:
(http://www.scienceblogs.com/Insolence)

lilady comments on “Orac’s”:
(http://www.scienceblogs.com/Insolence)

Peter Lipson (@palMD)
http://www.sciencebasedmedicine.org

http://www.sciencebasedmedicine.org/index.php/author/palmd/

http://www.sciencebasedmedicine.org/index.php/editorial-staff/peter-a-lipson-md/

Dr. David H. Gorski (“Orac,” @gorskon, @oracknows, @ScienceBasedMed, #sciencebasedmedicine
runs:
http://www.scienceblogs/Insolence
and is the editor of:
http://www.sciencebasedmedicine.org
and is a “pal” of his “bud:”. Dr. Peter A. Lipson)

Paul Morgan (@drpaulmorgan)

Paul Morgan comments on “Orac’s”:
(http://www.scienceblogs.com/Insolence)

What do all of those “Skeptic” Critics have in common?

Dr. David H. Gorski (“Orac”)

Forbes censors Peter Lipson “Speech is best countered by more speech” article comments:
https://stanislawrajmundburzynski.wordpress.com/2013/04/23/forbes-censors-peter-lipson-speech-is-best-countered-by-more-speech-article-comments/

Boris Ogon (@borisogon)

“You are right now having a live “debate” in front of more than 10,000 people, … “

3,921 views

Not so much

Waiting for the 10,000

4/19/2013 @ 9:43PM

A Film Producer, A Cancer Doctor, And Their Critics

Peter Lipson:-“Speech is best countered by more speech”

Advertisements

One thought on “Forbes Learns a Lesson, but Not the Right One: Censorship and Bias re: A Film Producer, A Cancer Doctor, And Their Critics

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s